Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [1] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy
    Kudo, Toshihiro
    Kato, Takeshi
    Kagawa, Yoshinori
    Sakai, Daisuke
    Satoh, Taroh
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
    Kudo, T.
    Kato, T.
    Kagawa, Y.
    Murata, K.
    Ohta, H.
    Noura, S.
    Hasegawa, J.
    Tamagawa, H.
    Ohta, K.
    Ikenaga, M.
    Miyazaki, S.
    Komori, T.
    Nishimura, J.
    Hata, T.
    Matsuda, C.
    Satoh, T.
    Mizushima, T.
    Yamamoto, H.
    Doki, Y.
    Mori, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
    Kato, Takeshi
    Kudo, Toshihiro
    Kagawa, Yoshinori
    Murata, Kohei
    Ota, Hirofumi
    Noura, Shingo
    Hasegawa, Junichi
    Tamagawa, Hiroshi
    Ohta, Katsuya
    Ikenaga, Masakazu
    Miyazaki, Susumu
    Komori, Takamichi
    Uemura, Mamoru
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Satoh, Taroh
    Mizushima, Tsunekazu
    Ohno, Yuko
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Eguchi, Hidetoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [4] Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
    Takeshi Kato
    Toshihiro Kudo
    Yoshinori Kagawa
    Kohei Murata
    Hirofumi Ota
    Shingo Noura
    Junichi Hasegawa
    Hiroshi Tamagawa
    Katsuya Ohta
    Masakazu Ikenaga
    Susumu Miyazaki
    Takamichi Komori
    Mamoru Uemura
    Junichi Nishimura
    Taishi Hata
    Chu Matsuda
    Taroh Satoh
    Tsunekazu Mizushima
    Yuko Ohno
    Hirofumi Yamamoto
    Yuichiro Doki
    Hidetoshi Eguchi
    Scientific Reports, 13
  • [5] Phase II study on starting with reduced dose of regorafenib for metastatic colorectal cancer after standard chemotherapy
    Ota, Hirofumi
    Kagawa, Yoshinori
    Ohta, Katsuya
    Miyazaki, Susumu
    Hamabe, Atsushi
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Mori, Masaki
    CANCER SCIENCE, 2018, 109 : 307 - 307
  • [6] Regorafenib dose-strategy in patients with metastatic colorectal cancer who progressed on standard treatment: A retrospective study
    Beninal, M.
    Belhadef, S.
    Bacha, N.
    Arab, A.
    Mechta, K.
    Dahmane, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S200 - S200
  • [7] Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    Ou, Fang-Shu
    Ciombor, Kristen Keon
    Farhat, Mohamed I.
    Kirshner, Jeffrey J.
    Knost, James A.
    Anderson, Daniel M.
    Soori, Gamini S.
    Boland, Patrick Mckay
    Wender, Donald B.
    Desnoyers, Rodwige J.
    Sargent, Daniel J.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Regorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT study
    Falcone, A.
    Van Cutsem, E.
    Sobrero, A.
    Siena, S.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S546 - S546
  • [9] Regorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT study
    Karthaus, M.
    Falcone, A.
    van Cutsem, E.
    Sobrero, A.
    Siena, S.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 39 - 39
  • [10] REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
    Klajer, E.
    Jary, M.
    Borg, C.
    Kim, S.
    Vernerey, D.
    Henriques, J.
    N'Guyen, T.
    Nasri, M.
    Almotlak, H.
    Babre, J.
    Meurisse, A.
    Fratte, S.
    Fein, F.
    Calcagno, F.
    Chanut, L.
    Spehner, L.
    Rebucci-Peixoto, M.
    Vienot, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S581 - S581
12345